1. Klinik für Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany; 2. Department of Cardiology, Oslo University Hospital Ullevål, University of Oslo, Oslo, Norway
Hypertension is a major cardiovascular risk factor, and despite the availability of effective antihypertensive drugs the percentage of patients with blood pressure at target values remains low. Especially patients who cannot be controlled by conventional drug treatment are at increased risk of cardiovascular events, which supports the need for greater efforts toward improving hypertension outcomes in this population1. Recently, catheter-based renal denervation has been introduced into the market as a new and promising technology to reduce sympathetic activity and blood pressure in patients with resistant hypertension2. The first-in man (FIM) study was performed using a radiofrequency-based approach (Symplicity, Ardian/Medtronic, ...
Sign in to read and download the full articleForgot your password?
No account yet? Sign up for free!Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com